The Orphan Drug designation is based on data from the dose escalation phase of the open-label phase 1/2 study.

The lead drug emerging from the biotech's Helicon platform is billed as a "first-and-only-in-class" direct TCF-blocking beta-catenin inhibitor, which FogPharma says has potential as a treatment ...